Moderna Inc (MRNA)
Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company focused on messenger RNA medicines. The company develops and commercializes products across several therapeutic areas, including respiratory vaccines, latent virus vaccines, enteric virus vaccines, public health vaccines, bacterial disease vaccines, oncology therapeutics, and rare disease products. Its respiratory vaccine portfolio includes products and candidates for COVID, RSV, seasonal influenza, combination vaccines, and pandemic influenza. Moderna also works on programs in cytomegalovirus, Epstein-Barr virus, HIV, norovirus, Zika, Nipah, Mpox, and Lyme disease, along with treatments for propionic acidemia, methylmalonic acidemia, and cystic fibrosis.
The company has entered into strategic collaborations with Merck & Co., Vertex Pharmaceuticals, immatics N.V., DARPA, BARDA, the Institute for Life Changing Medicines, The Bill & Melinda Gates Foundation, and OpenAI. Founded in 2010, the company was previously known as Moderna Therapeutics, Inc. before adopting its current name in 2018.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MRNA
|
$96.13
|
-37.6% Downside
|
Overvalued
|
$119.56
|
-22.4% Downside
|
Overvalued
|
Good
|
0.0%
|
October 29, 2026
|
9.1x
|
27.6x
|
61.522 B
|
55.875 B
|
2.0%
|
93.2%
|
9.3
|
39.5%
|
